- Home
- ATOS vs NCSM Comparison
ATOS vs NCSM Comparison
Compare ATOS & NCSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- NCSM
- Stock Information
- Founded
- ATOS 2009
- NCSM 2006
- Country
- ATOS United States
- NCSM United States
- Employees
- ATOS N/A
- NCSM N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- NCSM Oilfield Services/Equipment
- Sector
- ATOS Health Care
- NCSM Energy
- Exchange
- ATOS Nasdaq
- NCSM Nasdaq
- Market Cap
- ATOS 106.9M
- NCSM 97.3M
- IPO Year
- ATOS 2012
- NCSM 2017
- Fundamental
- Price
- ATOS $0.77
- NCSM $35.46
- Analyst Decision
- ATOS Strong Buy
- NCSM
- Analyst Count
- ATOS 3
- NCSM 0
- Target Price
- ATOS $6.25
- NCSM N/A
- AVG Volume (30 Days)
- ATOS 539.9K
- NCSM 14.4K
- Earning Date
- ATOS 11-12-2025
- NCSM 10-29-2025
- Dividend Yield
- ATOS N/A
- NCSM N/A
- EPS Growth
- ATOS N/A
- NCSM N/A
- EPS
- ATOS N/A
- NCSM 4.53
- Revenue
- ATOS N/A
- NCSM $178,000,000.00
- Revenue This Year
- ATOS N/A
- NCSM $11.91
- Revenue Next Year
- ATOS N/A
- NCSM $7.63
- P/E Ratio
- ATOS N/A
- NCSM $8.19
- Revenue Growth
- ATOS N/A
- NCSM 16.49
- 52 Week Low
- ATOS $0.55
- NCSM $20.00
- 52 Week High
- ATOS $1.36
- NCSM $53.69
- Technical
- Relative Strength Index (RSI)
- ATOS 34.80
- NCSM 42.24
- Support Level
- ATOS $0.77
- NCSM $34.06
- Resistance Level
- ATOS $0.85
- NCSM $37.40
- Average True Range (ATR)
- ATOS 0.05
- NCSM 2.05
- MACD
- ATOS -0.01
- NCSM -0.03
- Stochastic Oscillator
- ATOS 18.62
- NCSM 32.44
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About NCSM NCS Multistage Holdings Inc.
NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completions and field development strategies. NCS provides its products and services to exploration and production companies for use in onshore wells, predominantly wells that have been drilled with horizontal laterals in unconventional oil and natural gas formations. The company's offering is its fracturing systems products and services, which enable efficient pinpoint stimulation: the process of individually stimulating each entry point into a formation targeted by an oil or natural gas well. It sell products and services in North America and in selected international markets.